Deadline Looms for Hims & Hers Investors in Securities Litigation

Telehealth provider Hims & Hers Health, Inc. faces a critical juncture as the August 25, 2025, deadline passes for shareholders to file as lead plaintiffs in a consolidated class action. The lawsuit alleges the company misled investors about its business practices, particularly within its lucrative weight-loss medication segment, triggering a significant crisis of investor confidence.

Partnership Collapse and Stock Plunge

The situation escalated dramatically on June 23, 2025, when pharmaceutical giant Novo Nordisk officially terminated its partnership with Hims & Hers. The Danish company cited concerns over its partner’s “deceptive practices” as the reason for severing ties.

Financial markets reacted immediately and severely. On the day of the announcement, Hims & Hers shares plummeted by 34%, erasing a substantial portion of market value in a single session and cementing shareholder losses.

Core Allegations: Misrepresentation and Concealed Risks

The legal complaint levels serious accusations against the company and its leadership. Central to the case is the claim that Hims & Hers knowingly promoted and distributed illegitimate compounded alternatives to Novo Nordisk’s branded weight-loss drug, Wegovy®. This activity, the suit alleges, potentially endangered patient safety.

Should investors sell immediately? Or is it worth buying Hims & Hers?

A further, more damaging accusation suggests company executives concealed material business risks from investors. Specifically, the litigation claims leadership failed to disclose the significant threat that Novo Nordisk would dissolve their partnership, thereby presenting an unduly positive picture of the company’s stability and growth trajectory.

Regulatory Scrutiny Intensifies

Compounding the civil litigation, Hims & Hers now appears to be under scrutiny from the U.S. Federal Trade Commission (FTC). Reports indicate the regulatory body is examining the company’s advertising methods and subscription model practices, adding a layer of regulatory risk to its existing legal challenges.

The convergence of a major class action and a potential federal investigation places Hims & Hers in a precarious position. The expiration of the lead plaintiff deadline marks a pivotal moment in this unfolding corporate drama, raising fundamental questions about the long-term impact on the company’s reputation and business model.